Summary of significant treatment × time effect. حسب Wensheng Xiao (16557866)

Summary of significant single-arm time effect. حسب Wensheng Xiao (16557866)

The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx حسب Jianhong Ren (2186293)

"…Compared with IND, IHD did not significantly improve the population yield. The upper leaf area of intercropped XY was greater than sole stand, leading to increased interception of photosynthetically active radiation (PAR). …"

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Structural equation models raw data. حسب K. Kanoho Hosoda (19929050)

الموضوعات:

Summary of sample descriptive statistics. حسب K. Kanoho Hosoda (19929050)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Microhardness of various samples. حسب Huashen Guan (20454677)

الموضوعات:

Shot peening process parameters. حسب Huashen Guan (20454677)

الموضوعات:

Wear morphology: (a) UT, (b) SP1, (c) SP2, and (d) SP3. حسب Huashen Guan (20454677)

الموضوعات:

Schematic diagram of pin-disk wear. حسب Huashen Guan (20454677)

الموضوعات:

Surface 3D topography (a) UT, (b) SP1, (c) SP2, (d) SP3. حسب Huashen Guan (20454677)

الموضوعات:

Parameters of the sliding wear test. حسب Huashen Guan (20454677)

الموضوعات: